Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complete Response Clear all
Completed Phase 2 Interventional Results available

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

NCT00791778
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 2, 2026, 12:40 PM EDT
Recruiting Phase 2 Interventional

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

NCT07407920
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Hormone Therapy, Pembrolizumab, Pertuzumab, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Active, not recruiting Not applicable Interventional

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

NCT03460067
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Omission of Radiation
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Completed No phase listed Observational

Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting

NCT02232711
View directory record Official record
Conditions
Upper Respiratory Infections
Interventions
Not listed
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Not listed
Enrollment
1,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
San Diego, California • St Louis, Missouri • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

NCT00725283
View directory record Official record
Conditions
Leukaemia, Myelocytic, Acute
Interventions
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
9
States / cities
Tampa, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 2, 2026, 12:40 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 2, 2026, 12:40 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

NCT07217990
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions
Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection
Drug · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Suspended Phase 1Phase 2 Interventional

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 2 Interventional

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

NCT03188393
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Biopsy of Breast
Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
377
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 256 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

NCT00005062
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 2, 2026, 12:40 PM EDT
Recruiting Phase 2 Interventional

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

NCT07400029
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Obecabtagene Autoleucel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Duarte, California • Stanford, California • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

NCT01401959
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 2, 2026, 12:40 PM EDT
Recruiting Phase 1 Interventional

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

NCT05535855
View directory record Official record
Conditions
Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Interventions
CD19 Directed CAR T Cell
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Not applicable Interventional Results available

Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants

NCT03694613
View directory record Official record
Conditions
Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
Interventions
Placental/Umbilical Cord Blood sample
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 1 Day
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 2, 2026, 12:40 PM EDT
Not listed Phase 4 Interventional

Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19

NCT04603794
View directory record Official record
Conditions
COVID-19
Interventions
0.5% Povidone Iodine, 0.12% Chlorhexidine Gluconate Mouth Rinse, 1% Hydrogen Peroxide, 0.9% Normal Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 2, 2026, 12:40 PM EDT
Terminated No phase listed Observational

Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

NCT02991547
View directory record Official record
Conditions
Adenocarcinoma Esophagus
Interventions
Observational
Other
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Corning, New York • Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 2, 2026, 12:40 PM EDT
Recruiting Phase 2 Interventional

Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

NCT06526338
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone
Drug · Procedure
Lead sponsor
Robert C. Martin
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

NCT03070093
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
32
States / cities
Los Angeles, California • Aurora, Colorado • Pembroke Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

NCT01543087
View directory record Official record
Conditions
Meningococcal Infection
Interventions
blood sampling, bivalent rLP2086
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
36
States / cities
Chandler, Arizona • Huntington Beach, California • Paramount, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 2, 2026, 12:40 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT01818063
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Veliparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Terminated Early Phase 1 Interventional

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

NCT02966730
View directory record Official record
Conditions
Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade IIIa
Interventions
Ibrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 2, 2026, 12:40 PM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 2, 2026, 12:40 PM EDT